Summit Therapeutics, Inc. (SMMT)
16.76
+0.06
(+0.39%)
USD |
NASDAQ |
Oct 02, 16:00
16.75
0.00 (0.00%)
After-Hours: 04:01
Summit Therapeutics Net Income (Quarterly) : -215.70M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -215.70M |
| March 31, 2026 | -189.42M |
| December 31, 2025 | -219.17M |
| September 30, 2025 | -231.79M |
| June 30, 2025 | -565.71M |
| March 31, 2025 | -62.91M |
| December 31, 2024 | -61.20M |
| September 30, 2024 | -56.25M |
| June 30, 2024 | -60.38M |
| March 31, 2024 | -43.47M |
| December 31, 2023 | -36.60M |
| September 30, 2023 | -21.27M |
| June 30, 2023 | -14.72M |
| March 31, 2023 | -542.38M |
| December 31, 2022 | -19.23M |
| September 30, 2022 | -21.38M |
| June 30, 2022 | -16.77M |
| March 31, 2022 | -21.40M |
| December 31, 2021 | -27.10M |
| September 30, 2021 | -19.60M |
| June 30, 2021 | -24.42M |
| March 31, 2021 | -17.49M |
| December 31, 2020 | -13.54M |
| September 30, 2020 | -17.74M |
| Date | Value |
|---|---|
| June 30, 2020 | -15.28M |
| March 31, 2020 | -6.308M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | -6.616M |
| October 31, 2018 | -10.56M |
| July 31, 2018 | 35.44M |
| April 30, 2018 | -8.184M |
| January 31, 2018 | -15.20M |
| October 31, 2017 | -1.137M |
| July 31, 2017 | -4.236M |
| April 30, 2017 | -5.943M |
| January 31, 2017 | -6.116M |
| October 31, 2016 | -5.891M |
| July 31, 2016 | -8.968M |
| April 30, 2016 | -7.762M |
| January 31, 2016 | -7.466M |
| October 31, 2015 | -7.182M |
| July 31, 2015 | -6.262M |
| April 30, 2015 | -5.075M |
| January 31, 2015 | -4.669M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0858M |
| Brainstorm Cell Therapeutics, Inc. | -3.855M |
| Kezar Life Sciences, Inc. | -5.756M |
| Protara Therapeutics, Inc. | -21.67M |
| Clene, Inc. | -13.42M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 215.70M |
| EPS Diluted (Quarterly) | -0.2772 |
| Enterprise Value | 12.62B |
| Earnings Yield | -6.68% |
| Normalized Earnings Yield | -6.680 |